All News

Company faces two Vioxx setbacks in court as it prepares to reveal safety data on its cox-2 successor.

Recent analysis shows partial or complete invalidation of all pharma patents challenged since December 2004.

Schering-Plough's successful allergy medication gets an updated ad campaign.

Revolutionizing Pharmaceutical Marketing Effectiveness with Change Management and Technology

Revolutionizing Pharmaceutical Marketing Effectiveness with Change Management and Technology

Bioterrorism and larger profit margins could drive future growth.

Legal experts question how reverse payment deal went so awry.

Biotechs find sales more profitable than IPOs.

Partnership with Momenta includes technology to evaluate bio-equivalence.

Online advertising opportunities

Think you've been around a long time? When's the last time your company gave a doctor a cigarette lighter with your logo on it? Put any corks in medicine bottles lately? Can you remember the last hero shot of a pharma CEO on the cover of Time? We can. And we have the artifacts to prove it...

Do you remember where you were when Mevacor was approved? OK, what was on the radio at the time?

Is the golden age of drug development over? Fat chance. Decade-by-decade comparisons show how new medicines improve on old ones. And that's innovation.

Pharma restrictions of sales tactics vary from state to state, creating new compliance challenges.

The road forward for both public health and the industry is going to require more trust and intimacy, not less, between patients, physicians, FDA, and pharma. Patients need to see a fully functioning set of checks and balances-not what they're seeing today.

Pharma leaders (and Pharm Exec readers) reflect on the ideas and events that revolutionized the industry over the last quarter of a century--and what to watch for in the next 25.

See how well you did on Pharmaceutical Executive's 25th anniversary quiz.

In 1981, when Pharm Exec published its first issue, the pharmaceutical world was a very different place: There was no direct-to-consumer advertising, no map of the genome, no high-speed screening of millions of compounds. The process of marketing and selling drugs was discreet and nearly invisible to the public; and sales forces, by today's standards, were minuscule. The first biotechs had just launched; and the Bayh-Dole Act, passed the year before, had begun to lay the groundwork for the explosion of research-driven university spin-off companies that transformed the face of research in the 1990s.

In 1981, pharma was a more innocent industry. It stood on the brink of an AIDS epidemic that science had yet to name or understand. Hazards of generics, product lifecycles, and off-label marketing lay years ahead. There were no embryonic stem cells to fight over--nor euphemisms like "overactive bladder syndrome" and "erectile dysfunction" to ease conversations or kick off ad campaigns. Who knew what awaited us? To remember--and to reflect on what shaped modern pharma--we invite you to page through the most significant events of the past quarter century.

August 2006 CE.

Deal combines Crestor with either TriCor or experimental fibrate.

AMA says enrollment depends on physicians' experiences with drug reps.

Our 7th Annual Report on the World?s Top 50 Pharmaceutical Companies [Revised]

Drug giants explain sale of Pfizer's consumer business.

McKesson's new program helps build bridges.

Branded drug makers hand generic companies a new challenge.

Pharma companies fear CMS' new Medicare policy will routinely require post-approval studies in order to gain reimbursement for new drugs. CMS says it is expanding payment for "promising but not persuasive" drugs.

Whether you're gay or straight, or African-American, white or Hispanic, we knew that we have an audience that is very diverse and experiences the disease in very different ways. Telling the stories in serial format was best.

At first glance, you might think Bob Miglani comes from a pharma family. He and both of his younger sisters began their careers as sales reps after college. But behind their success in big business lie formative experiences at the Dairy Queen stores owned by their uncle and parents, who are immigrants from India. Even today, Miglani, whose fulltime job is in Pfizer's public affairs department, spends some weekends serving cones at the family business. In his new book, Treat Your Customers: Thirty Lessons on Service and Sales That I Learned at My Family's Dairy Queen Store (Hyperion, 2006), Miglani, 36, shares the core values that work in small business and corporate America.

July 2006 CE.